These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27628662)

  • 1. Some HER2-Negative Breast Tumors May Respond to HER2-Targeted Treatment.
    Rochman S
    J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628662
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 4. Palbociclib: an approval at last for HER2-negative breast cancer.
    Zerdes I; Ziogas DE; Lykoudis EG; Roukos DH
    Future Oncol; 2016 May; 12(9):1097-100. PubMed ID: 26987714
    [No Abstract]   [Full Text] [Related]  

  • 5. Pertuzumab: development beyond breast cancer.
    Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
    Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
    Tuma RS
    J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
    [No Abstract]   [Full Text] [Related]  

  • 7. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 8. Where to with HER2?
    Sledge GW
    Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 10. T-DM1 Extends Survival in HER2+ Breast Cancer.
    Cancer Discov; 2016 Feb; 6(2):OF4. PubMed ID: 26676162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
    D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
    Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological considerations and clinical applications of new HER2-targeted agents.
    Higa GM; Singh V; Abraham J
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1497-509. PubMed ID: 20836684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.
    Di Modica M; Tagliabue E; Triulzi T
    Dis Markers; 2017; 2017():7849108. PubMed ID: 29403144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of HER2 testing in the management of breast cancer.
    Ravdin P
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated HER2: implications for HER2-targeted therapeutics.
    Zagozdzon R; Gallagher WM; Crown J
    Drug Discov Today; 2011 Sep; 16(17-18):810-6. PubMed ID: 21704182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035).
    Tartari F; Santoni M; Pistelli M; Berardi R
    Cancer Treat Rev; 2017 Nov; 60():12-17. PubMed ID: 28863312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.